Inotiv, Inc. (NOTV)

Market Cap	110.64M
Revenue (ttm)	585.17M
Net Income (ttm)	-33.21M
Shares Out	25.79M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	587,486
Open	4.640
Previous Close	4.700
Day's Range	4.290 - 4.810
52-Week Range	1.610 - 11.420
Beta	3.20
Analysts	Strong Buy
Price Target	15.17 (+253.61%)
Earnings Date	May 9, 2024

About NOTV

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial p...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 24, 1997
• Employees: 1,955
• Stock Exchange: NASDAQ
• Ticker Symbol: NOTV

Financial Performance

In 2023, Inotiv's revenue was $572.43 million, an increase of 4.52% compared to the previous year's $547.66 million. Losses were -$105.14 million, -68.80% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for NOTV stock is "Strong Buy." The 12-month stock price forecast is $15.17, which is an increase of 253.61% from the latest price.

Price Target

$15.17

(253.61% upside)

Analyst Consensus: Strong Buy